Nanocomplex‐Mediated In Vivo Programming to Chimeric Antigen Receptor‐M1 Macrophages for Cancer Therapy

Chimeric antigen receptor‐T (CAR‐T) cell immunotherapy has shown impressive clinical outcomes for hematologic malignancies. However, its broader applications are challenged due to its complex ex vivo cell‐manufacturing procedures and low therapeutic efficacy against solid tumors. The limited therapeutic effects are partially due to limited CAR‐T cell infiltration to solid tumors and inactivation of CAR‐T cells by the immunosuppressive tumor microenvironment. Here, a facile approach is presented to in vivo program macrophages, which can intrinsically penetrate solid tumors, into CAR‐M1 macrophages displaying enhanced cancer‐directed phagocytosis and anti‐tumor activity. In vivo injected nanocomplexes of macrophage‐targeting nanocarriers and CAR‐interferon‐γ‐encoding plasmid DNA induce CAR‐M1 macrophages that are capable of CAR‐mediated cancer phagocytosis, anti‐tumor immunomodulation, and inhibition of solid tumor growth. Together, this study describes an off‐the‐shelf CAR‐macrophage therapy that is effective for solid tumors and avoids the complex and costly processes of ex vivo CAR‐cell manufacturing.

[1]  Z. Duan,et al.  Targeting macrophages in cancer immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[2]  Xuefeng Gao,et al.  The Advances and Challenges of NK Cell-Based Cancer Immunotherapy , 2021, Current oncology.

[3]  Jianguo Wang,et al.  Targeting tumor-associated macrophages to synergize tumor immunotherapy , 2021, Signal Transduction and Targeted Therapy.

[4]  G. Dotti,et al.  Delivery Techniques for Enhancing CAR T Cell Therapy against Solid Tumors , 2021, Advanced Functional Materials.

[5]  M. Maus,et al.  Recent advances and discoveries in the mechanisms and functions of CAR T cells , 2021, Nature Reviews Cancer.

[6]  S. Boye,et al.  Current Clinical Applications of In Vivo Gene Therapy with AAVs , 2020, Molecular therapy : the journal of the American Society of Gene Therapy.

[7]  M. Caligiuri,et al.  Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy , 2020, Journal of Hematology & Oncology.

[8]  He Huang,et al.  Engineering better chimeric antigen receptor T cells , 2020, Experimental Hematology & Oncology.

[9]  Kazuhiro Yoshida,et al.  M1 Macrophage and M1/M2 ratio defined by transcriptomic signatures resemble only part of their conventional clinical characteristics in breast cancer , 2020, Scientific Reports.

[10]  Liping Wang,et al.  Roles of IFN-γ in tumor progression and regression: a review , 2020, Biomarker Research.

[11]  Jianzhu Chen,et al.  CAR-NK cells: A promising cellular immunotherapy for cancer , 2020, EBioMedicine.

[12]  Shuhua Wei,et al.  Regulatory T cells in tumor microenvironment: new mechanisms, potential therapeutic strategies and future prospects , 2020, Molecular Cancer.

[13]  D. Powell,et al.  CAR-T Cells Hit the Tumor Microenvironment: Strategies to Overcome Tumor Escape , 2020, Frontiers in Immunology.

[14]  C. June,et al.  A rational mouse model to detect on-target off-tumor CAR T cell toxicity. , 2020, JCI insight.

[15]  Lily Yang,et al.  Targeted Imaging of CD206 Expressing Tumor-Associated M2-like Macrophages Using Mannose-Conjugated Antibiofouling Magnetic Iron Oxide Nanoparticles. , 2020, ACS applied bio materials.

[16]  M. Serafini,et al.  Transposon-Based CAR T Cells in Acute Leukemias: Where Are We Going? , 2020, Cells.

[17]  Kamir J. Hiam,et al.  Systemic dysfunction and plasticity of the immune macroenvironment in cancer models , 2020, Nature Medicine.

[18]  Y. Beck,et al.  Immune Checkpoint Inhibition Followed by Tumor Infiltration of Dendritic Cells in Murine Neuro-2a Neuroblastoma. , 2020, The Journal of surgical research.

[19]  Chem. , 2020, Catalysis from A to Z.

[20]  Martha E. Zeeman,et al.  Human chimeric antigen receptor macrophages for cancer immunotherapy , 2020, Nature Biotechnology.

[21]  Jonathan Smith,et al.  Optimizing CAR-T Cell Manufacturing Processes during Pivotal Clinical Trials , 2019, Molecular therapy. Methods & clinical development.

[22]  R. Brentjens,et al.  Engineering strategies to overcome the current roadblocks in CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[23]  S. Reddy,et al.  Molecular Design, Optimization, and Genomic Integration of Chimeric B Cell Receptors in Murine B Cells , 2019, Front. Immunol..

[24]  Pingping Shen,et al.  Chimeric antigen receptor macrophage therapy for breast tumours mediated by targeting the tumour extracellular matrix , 2019, British Journal of Cancer.

[25]  Qi Huang,et al.  Nanoparticles Targeting Macrophages as Potential Clinical Therapeutic Agents Against Cancer and Inflammation , 2019, Front. Immunol..

[26]  A. McLellan,et al.  Chimeric antigen receptor T cell persistence and memory cell formation , 2019, Immunology and cell biology.

[27]  J. Joyce,et al.  Re-education of macrophages as a therapeutic strategy in cancer. , 2019, Immunotherapy.

[28]  T. Fry,et al.  Mechanisms of resistance to CAR T cell therapy , 2019, Nature Reviews Clinical Oncology.

[29]  D. Powell,et al.  The Emergence of Universal Immune Receptor T Cell Therapy for Cancer , 2019, Front. Oncol..

[30]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[31]  Zaidi Mr.  The Interferon-Gamma Paradox in Cancer , 2019 .

[32]  M. Najafi,et al.  Macrophage polarity in cancer: A review , 2018, Journal of cellular biochemistry.

[33]  M. Starnbach,et al.  The Vacuolar Pathway in Macrophages Plays a Major Role in Antigen Cross-Presentation Induced by the Pore-Forming Protein Sticholysin II Encapsulated Into Liposomes , 2018, Front. Immunol..

[34]  E. Sotillo,et al.  CAR T Cell Therapy for Neuroblastoma , 2018, Front. Immunol..

[35]  R. Parkhouse,et al.  Impact of the GK-1 adjuvant on peritoneal macrophages gene expression and phagocytosis. , 2018, Immunology letters.

[36]  Y. Okuno,et al.  Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR , 2018, EBioMedicine.

[37]  L. Ivashkiv.  IFNγ: signalling, epigenetics and roles in immunity, metabolism, disease and cancer immunotherapy , 2018, Nature Reviews Immunology.

[38]  Hans Bitter,et al.  Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia , 2018, Nature Medicine.

[39]  G. Holländer,et al.  CAR-T Cells: A Systematic Review and Mixed Methods Analysis of the Clinical Trial Landscape. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[40]  S. Akhtar,et al.  Mannosylated thiolated polyethylenimine nanoparticles for the enhanced efficacy of antimonial drug against Leishmaniasis. , 2018, Nanomedicine.

[41]  A. Zajakina,et al.  Generation and Functional In Vitro Analysis of Semliki Forest Virus Vectors Encoding TNF-α and IFN-γ , 2017, Front. Immunol..

[42]  Hanmei Xu,et al.  Tumor-related interleukins: old validated targets for new anti-cancer drug development , 2017, Molecular Cancer.

[43]  Hao Liu,et al.  CAR T Cells Administered in Combination with Lymphodepletion and PD-1 Inhibition to Patients with Neuroblastoma. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[44]  R. Orentas,et al.  Tumor Antigen and Receptor Densities Regulate Efficacy of a Chimeric Antigen Receptor Targeting Anaplastic Lymphoma Kinase. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[45]  J. Bartek,et al.  Polyplex Evolution: Understanding Biology, Optimizing Performance. , 2017, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Chao Yang,et al.  Adenovirus-mediated gene delivery: Potential applications for gene and cell-based therapies in the new era of personalized medicine , 2017, Genes & diseases.

[47]  Matthias T Stephan,et al.  In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers. , 2017, Nature nanotechnology.

[48]  Jesse D. Ziebarth,et al.  Structural Comparisons of PEI/DNA and PEI/siRNA Complexes Revealed with Molecular Dynamics Simulations. , 2017, The journal of physical chemistry. B.

[49]  J. Wargo,et al.  Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy , 2017, Cell.

[50]  Xiaoai Wu,et al.  Targeted Imaging of Tumor-Associated Macrophages by Cyanine 7-Labeled Mannose in Xenograft Tumors , 2017, Molecular imaging.

[51]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[52]  Krutika K Sawant,et al.  Polyethylenimine: A versatile, multifunctional non-viral vector for nucleic acid delivery. , 2016, Materials science & engineering. C, Materials for biological applications.

[53]  K. Curran,et al.  Toxicity and management in CAR T-cell therapy , 2016, Molecular therapy oncolytics.

[54]  Yu‐quan Wei,et al.  Special Topic: Fighting Cancer with Armed T Cells Hurdles of Car-t Cell-based Cancer Immunotherapy Directed against Solid Tumors , 2022 .

[55]  D. Kranz,et al.  Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors. , 2016, Trends in pharmacological sciences.

[56]  A. Chaudhuri,et al.  Genetic Immunization With In Vivo Dendritic Cell-targeting Liposomal DNA Vaccine Carrier Induces Long-lasting Antitumor Immune Response , 2015, Molecular Therapy.

[57]  V. Bitko,et al.  The Functionality of Minimal PiggyBac Transposons in Mammalian Cells. , 2016, Molecular therapy. Nucleic acids.

[58]  C. Rooney,et al.  Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells , 2015, Nucleic acids research.

[59]  Vivien W. Chan,et al.  Macrophage IL-10 blocks CD8+ T cell-dependent responses to chemotherapy by suppressing IL-12 expression in intratumoral dendritic cells. , 2014, Cancer cell.

[60]  Q. Sattentau,et al.  Polyethyleneimine is a potent systemic adjuvant for glycoprotein antigens. , 2014, International immunology.

[61]  Abhay Asthana,et al.  Mannosylated Chitosan Nanoparticles for Delivery of Antisense Oligonucleotides for Macrophage Targeting , 2014, BioMed research international.

[62]  Z. Cui,et al.  Targeting of tumor-associated macrophages made possible by PEG-sheddable, mannose-modified nanoparticles. , 2013, Molecular pharmaceutics.

[63]  I. Mellman,et al.  Oncology meets immunology: the cancer-immunity cycle. , 2013, Immunity.

[64]  T. Ørntoft,et al.  Tumor‐promoting macrophages induce the expression of the macrophage‐specific receptor CD163 in malignant cells , 2012, International journal of cancer.

[65]  Zhi-ren Zhang,et al.  Macrophages in Tumor Microenvironments and the Progression of Tumors , 2012, Clinical & developmental immunology.

[66]  Y. Mossé,et al.  Targeting ALK in neuroblastoma—preclinical and clinical advancements , 2012, Nature Reviews Clinical Oncology.

[67]  Ashley M. Jacobi,et al.  Synthesis and characterization of mannosylated pegylated polyethylenimine as a carrier for siRNA. , 2012, International journal of pharmaceutics.

[68]  I. Weissman,et al.  The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications. , 2012, Current opinion in immunology.

[69]  A. Mantovani,et al.  Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm , 2010, Nature Immunology.

[70]  Richard A. Flavell,et al.  The polarization of immune cells in the tumour environment by TGFβ , 2010, Nature Reviews Immunology.

[71]  Matthew H. Wilson,et al.  PiggyBac transposon-based inducible gene expression in vivo after somatic cell gene transfer. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[72]  P. Allavena,et al.  Tumor‐associated macrophages (TAM) as major players of the cancer‐related inflammation , 2009, Journal of leukocyte biology.

[73]  J. Gu,et al.  Tumor-directed gene therapy in mice using a composite nonviral gene delivery system consisting of the piggyBac transposon and polyethylenimine , 2009, BMC Cancer.

[74]  S. Ogawa,et al.  Oncogenic mutations of ALK kinase in neuroblastoma , 2008, Nature.

[75]  D. Gary Gilliland,et al.  Activating mutations in ALK provide a therapeutic target in neuroblastoma , 2008, Nature.

[76]  E. Wagner,et al.  Simple modifications of branched PEI lead to highly efficient siRNA carriers with low toxicity. , 2008, Bioconjugate chemistry.

[77]  S. Carotta,et al.  DNA/polyethylenimine transfection particles: Influence of ligands, polymer size, and PEGylation on internalization and gene expression , 2001, AAPS PharmSci.

[78]  Alfred L George,et al.  PiggyBac transposon-mediated gene transfer in human cells. , 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

[79]  L. Mileshkin,et al.  In vivo tracking of macrophage activated killer cells to sites of metastatic ovarian carcinoma , 2006, Cancer Immunology, Immunotherapy.

[80]  John Condeelis,et al.  Macrophages: Obligate Partners for Tumor Cell Migration, Invasion, and Metastasis , 2006, Cell.

[81]  Min Han,et al.  Efficient Transposition of the piggyBac (PB) Transposon in Mammalian Cells and Mice , 2005, Cell.

[82]  Etienne Gagnon,et al.  Phagosomes are competent organelles for antigen cross-presentation , 2003, Nature.

[83]  S. Hart,et al.  Improved antitumour immunity in murine neuroblastoma using a combination of IL-2 and IL-12 , 2003, British Journal of Cancer.

[84]  Min Wu,et al.  Genetically engineered macrophages expressing IFN-γ restore alveolar immune function in scid mice , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[85]  Christian Bogdan,et al.  Nitric oxide and the immune response , 2001, Nature Immunology.

[86]  M. Chatterji,et al.  IFN-γ-Independent Autocrine Cytokine Regulatory Mechanism in Reprogramming of Macrophage Responses to Bacterial Lipopolysaccharide1 , 2001, The Journal of Immunology.

[87]  M. Cotten,et al.  Mannose Polyethylenimine Conjugates for Targeted DNA Delivery into Dendritic Cells* , 1999, The Journal of Biological Chemistry.